AKT1 E17K ‐Interacting lncRNA SVIL‐AS1 Promotes AKT1 Oncogenic Functions by Preferentially Blocking AKT1 E17K Dephosphorylation
Advanced Science · 2025
DOI: 10.1002/advs.202500919 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Jingyi Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, RNA, Long Noncoding, Breast Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Natural Science Foundation of China, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
AKT1 E17K is a gain‐of‐function mutation that constitutively activates the PI3K‐AKT pathway. However, how AKT1 E17K is regulated in cancer pathogenesis remains elusive. Here, RNA immunoprecipitation sequencing (RIP‐seq) is performed to interrogate the AKT1 E17K ‐interacting lncRNAs and identify that SVIL‐AS1 preferentially binds to AKT1 E17K rather than AKT1 WT proteins. It is found that SVIL‐AS1 enhances AKT1 phosphorylation and downstream signaling. SVIL‐AS1 knockdown dramatically inhibits the growth of AKT1 E17K cells in vitro and in vivo. Notably, AKT1 and SVIL‐AS1 interaction is AKT1 phosphorylation‐dependent. SVIL‐AS1 also interacts with PPP2R2A, a subunit of phosphatase PP2A holoenzyme, and blocks the binding of PPP2R2A to AKT1 E17K to prevent AKT1 dephosphorylation. Moreover, AKT1 E17K cells are not effectively inhibited by the allosteric AKT inhibitor, whereas silencing SVIL‐AS1 sensitizes AKT1 E17K cells to AKT1 allosteric inhibitor, as well as the PI3Kα inhibitor. In breast cancer tissues, SVIL‐AS1 is highly expressed and associated with p‐AKT1 level and poor prognosis of patients. Together, the findings discover a novel lncRNA regulator of mutant oncoprotein which preferentially prevents AKT1 E17K dephosphorylation. Targeting SVIL‐AS1 may help to improve the responses to inhibitors of the PI3K‐AKT pathway, especially in AKT1 E17K mutant tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
- Department of Gastroenterology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
- Department of Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China.
- Diagnosis and Treatment Center of Breast Diseases, Shantou Central Hospital, Shantou, 515031, China.
- Breast Cancer Center, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, 310022, China.
- Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
ORCID-Profile: Man-Li Luo
Förderung
- National Key Research and Development Program of China
- Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Guangdong S&T Program
- Key-Area Research and Development Program of Guangdong Province
- Guangdong Science and Technology Department
- National Natural Science Foundation of China
- Guangdong Provincial Department of Science and Technology
Zitieren
APA
Wang, J., Chen, W., Li, Q., Yang, R., Lin, X., Han, P., Huang, X., Hu, H., & Luo, M. L. (2025). AKT1 E17K ‐Interacting lncRNA SVIL‐AS1 Promotes AKT1 Oncogenic Functions by Preferentially Blocking AKT1 E17K Dephosphorylation. Advanced Science. https://doi.org/10.1002/advs.202500919
Vancouver
Wang J, Chen W, Li Q, Yang R, Lin X, Han P, et al. AKT1 E17K ‐Interacting lncRNA SVIL‐AS1 Promotes AKT1 Oncogenic Functions by Preferentially Blocking AKT1 E17K Dephosphorylation. Advanced Science. 2025. doi:10.1002/advs.202500919
BibTeX
@article{Wang2025,
author = {Wang, Jingyi and Chen, Wenying and Li, Qianying and Yang, Ruiyi and Lin, Xiaorong and Han, Ping and Huang, Xiaoming and Hu, Hai and Luo, Man-Li},
title = {AKT1 E17K ‐Interacting lncRNA SVIL‐AS1 Promotes AKT1 Oncogenic Functions by Preferentially Blocking AKT1 E17K Dephosphorylation},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202500919}
}
EUVIMED